Evidence map›Paper›PMID 38041756›Full record

ArticleMolecular and cellular biochemistry2024

Disrupting of IGF2BP3-stabilized HK2 mRNA by MYO16-AS1 competitively binding impairs LUAD migration and invasion.

Peiwei Li, Haibo Ge, Jiangfeng Zhao, Yongjia Zhou, Jie Zhou, Peichao Li, Junwen Luo, Wenhao Zhang, Zhongxian Tian, Xiaogang Zhao

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular and cellular biochemistry, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.4field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 9 citations in OpenAlex.

  1. Translational cancer research · 2026
    Article
  2. Review
  3. Article
  4. mFrontiers in cell and developmental biology · 2026
    Review
  5. LncRNANon-coding RNA research · 2025
    Article
  6. Application of mesenchymal stem cells in ferroptosis-related diseases.Journal of molecular medicine (Berlin, Germany) · 2025
    Review
  7. Review
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Peiwei LiInstitute of Medical Sciences, The Second Hospital of Shandong University, Jinan, China.
Haibo GeDepartment of Thoracic Surgery, The Second Hospital of Shandong University, Shandong University, No. 247 Beiyuan Street, Jinan, 250033, Shandong, China.
Jiangfeng ZhaoDepartment of Thoracic Surgery, The Second Hospital of Shandong University, Shandong University, No. 247 Beiyuan Street, Jinan, 250033, Shandong, China.
Yongjia ZhouDepartment of Thoracic Surgery, The Second Hospital of Shandong University, Shandong University, No. 247 Beiyuan Street, Jinan, 250033, Shandong, China.
Jie ZhouDepartment of Thoracic Surgery, The Second Hospital of Shandong University, Shandong University, No. 247 Beiyuan Street, Jinan, 250033, Shandong, China.
Peichao LiDepartment of Thoracic Surgery, The Second Hospital of Shandong University, Shandong University, No. 247 Beiyuan Street, Jinan, 250033, Shandong, China.
Junwen LuoDepartment of Thoracic Surgery, The Second Hospital of Shandong University, Shandong University, No. 247 Beiyuan Street, Jinan, 250033, Shandong, China.
Wenhao ZhangDepartment of Thoracic Surgery, The Second Hospital of Shandong University, Shandong University, No. 247 Beiyuan Street, Jinan, 250033, Shandong, China.
Zhongxian TianDepartment of Thoracic Surgery, The Second Hospital of Shandong University, Shandong University, No. 247 Beiyuan Street, Jinan, 250033, Shandong, China. tianzhongxian@email.sdu.edu.cn.
Xiaogang ZhaoDepartment of Thoracic Surgery, The Second Hospital of Shandong University, Shandong University, No. 247 Beiyuan Street, Jinan, 250033, Shandong, China. zhaoxiaogang@sdu.edu.cn.
Second Hospital of Shandong University · CN

Funding

Jinan Clinical Medicine Research Program for Thoracic Cancer 201912007National Natural Science Foundation of China 82002431
6 · The paper itself

Abstract

Since invasive cancer is associated with poor clinical outcomes, exploring the molecular mechanism underlying LUAD progression is crucial to improve the prognosis of patients with advanced disease. Herein, we found that MYO16-AS1 is expressed mainly in lung tissue but is notably downregulated in LUAD tissues. Overexpression of MYO16-AS1 inhibited the migration and invasion of LUAD cells. Mechanistic studies indicated that H3

Indexed as

Cell MovementHexokinaseNeoplasm InvasivenessRNA-Binding ProteinsRNA, MessengerAnimalsGene Expression Regulation, NeoplasticHumansLung NeoplasmsMiceRNA, Long NoncodingRNA StabilityHexokinaseHK2 protein, humanIGF2BP3 protein, humanRNA-Binding ProteinsRNA, Long NoncodingRNA, MessengerCancer invasionHK2IGF2BP3LUADMYO16-AS1

Identifiers

PMID38041756
PMCPMC11455711
OpenAlexW4389274896

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.